Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia

Haematologica

Volumn 90, Issue 6, 2005, Pages 776-784

  Ferrara, Felicetto ^a,c   D'Arco, Alfonso M ^b   De Simone, Mariacarla ^a   Mele, Giuseppina ^a   Califano, Catello ^b   Pocali, Barbara ^a   Danise, Paolo ^b   Palmieri, Salvatore ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b Ospedale Umberto I   (Italy)

^c NONE   (Italy)

Author keywords

Acute myeloid leukemia; Continuous infusion; cytarabine; Elderly patients; Fludarabine

Indexed keywords

AMPHOTERICIN B; BILIRUBIN; BUSULFAN; CIPROFLOXACIN; CYTARABINE; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; LIVER ENZYME;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN HEMORRHAGE; CANDIDIASIS; CD34 SELECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DEATH; DIARRHEA; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HYPOCALCEMIA; INFECTION; KAPLAN MEIER METHOD; KARYOTYPING; LENGTH OF STAY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PYREXIA IDIOPATHICA; STEM CELL MOBILIZATION; SURVIVAL TIME; THROMBOCYTE COUNT; TUMOR LYSIS SYNDROME;

AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VIDARABINE;

EID: 21244487395     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004;5:443-50.
2. Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004;50:197-222.
3. Schiffer CA. Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia. New Engl J Med 2003;349:727-9.
4. Ries LAG, Eisner MP, Kosary CL, Editors. SEER Cancer Statistics Review, 1973-1998. National Cancer Institute, Bethesda, MD, USA. 2001.
5. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
6. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukaemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001;39:275-87.
7. Ferrara F, Mirto S, Zagonel V, Pinto A. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. Leuk Lymphoma 1998;29: 375-82.
8. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89:3323-9.
9. Wahlin A, Markevam B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001;115:25-33.
10. Gandhi V, Estey E, Rearing MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11:116-24.
11. Tafuri A, Andreer M. Kinetic rationale for cytokine induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990;4:826-34.
12. Ferrara F, Palmieri S, Pocali B, Pollio F, Viola A, Annunziata S, et al. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur J Haematol 2002;68:203-9.
13. Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, et al. A multicentre open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 2001;112:127-37.
14. Ferrara F, Melillo L, Montillo M, Leoni F, Pinto A, Mele G, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ann Hematol 1999;78: 380-4.
15. Ferrara F, Leoni F, Pinto A, Mirto S, Morra E, Zagonel V, et al. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. Cancer 1999;86:2006-13.
16. Jackson GH. Use of fludarabine in the treatment of acute myeloid leukaemia. Hematology J 2004; 5 Suppl 1: S62-S7.
17. Clavio M, Gatto S, Beltrami G, Cerri R, Carrara P, Pierri I, et al. First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukemia. Leuk Lymphoma 2001;40:305-13.
18. Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol 2003;82:231-5.
19. Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, et al. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. J Clin Oncol 1997;15: 2780-5.
20. Vidarsson B, Abonour R, Williams EC, Woodson RD, Turman NJ, Kim K, et al. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. Leuk Lymphoma 2001;41:321-31.
21. Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin Cancer Res 1998;4:45-52.
22. Ferrara F, Mele G, Califano C, Palmieri S, Pocali B, Danise P, et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia. Blood 2002; 100:344a[abstract].
23. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
24. Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-transretinoic acid and chemotherapy. J Clin Oncol 2000;18:1295-300.
25. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
26. WHO Handbook for Reporting Results of Cancer Treatment. Vol. 38 World Health Organization. Geneva; 1979.
27. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukaemia. J Clin Oncol 2003; 21:4642-9.
28. Ferrara F, Palmieri S, Annunziata M, Viola A, Pocali B, Califano C, et al. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation. Bone Marrow Transplant 2004;34:573-6.
29. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
30. Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, et al. Decision-making and quality of life in older adults with acute myeloid leukaemia or advanced myelodysplastic syndrome. Leukemia 2004;18:809-16.
31. Ferrara F, Annunziata M, Copia C, Magrin S, Mele G, Mirto S. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia. Haematologica 1998;83:126-31.
32. Vey N, Coso D, Bardou VJ, Stoppa AM, Braud AC, Bouabdallah R, et al. The benefit of induction chemotherapy in patients age > 75 years. A retrospective study of 110 patients from a single institution. Cancer 2004;101: 325-31.
33. Gorin NC, Labopin M, Pichard P, Sierra J, Fiere D, Rio B, et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. Br J Haematol 2000;110:887-93.
34. Ferrara F, Venditti A, Carella Jr AM, Cantore N, Buccisano F, Tamburini A, et al. Autologous stem cell transplantation for patients with acute myeloid leukaemia aged over 60 years. Eur J Haematol 2002;69:200-4.
35. Massenkeil G, Nagy M, Lawang M, Rosen O, Genvresse I, Geserick G, et al. Arnold R. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003;31:339-45.
36. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003;102:3052-9.
37. Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S, et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol 2003;15: 3060-5.
38. Rathnasabapathy R, Lancet J. Management of acute myelogenous leukemia in the elderly. Cancer Control 2003;10: 469-77.
39. Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 2004;103:2908-13.
40. Estey EH. Prognostic factors in acute myeloid leukemia. Leukemia 2001;15: 670-2.
41. Lowenberg B. Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001;14:65-75.
42. Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukaemia. Haematologica 2004; 89:998-1008.
43. Haferlach T, Schoch C, Lof Her H, Gassmann W, Kern W. Schnittger S, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003;21:256-65.
44. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndromes. Blood 1999;93:2478-84.
45. Bruserud O, Tjonnfjord G, Gjertsen BT, Foss B, Ernst P. New strategies in the treatment of acute myelogenous leukemia: mobilization and transplantation of autologous peripheral blood stem cells in adult patients. Stem Cells 2000;18:343-51.
46. Ewing JC, Robertson JD, Kell WJ, Burnett AK, Ryder D, Chang J, et al. Autologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia - an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort. Hematology 2003;8:83-90.
47. + cells mobilization in acute leukemia: analysis of factors affecting the yield of progenitor cells. Bone Marrow Transplant 2004; 33:1083-7.
48. Carrai A, de la Rubia J, Martin G, Molla S, Martinez J, Sanz GF, et al. Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. Leuk Res 2003;27:5-12.
49. Rearing S, Suciu S, de Witte T, Zittoun R, Mandelli F, Belhabri A, et al. The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia 2003;17:60-7.
50. Visani G, Lemoli RM, Tosi P, Martinelli G, Testoni N, Ricci P, et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105:775-9.
51. Robak T. Purine nucleoside analogues in the treatment of myeloid leukemias. Leuk Lymphoma 2003;44:391-409.
52. Tournilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004;103:363-5.
53. Montillo M, Tedeschi A, Rossi V, Cairoli R, Pungolino E, Intropido L, et al. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia 2004;18:57-62.
54. Montillo M, Tedeschi A, Pagano L, Venditti A, Ferrara F, Fabris P, et al. Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the GIMEMA group. Br J Haematol 2000; 111:334-7.01.
55. Oriol A, Ribera JM, Esteve J, Guardia R, Brunet S, Bueno J, et al. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. Haematologica 2004;89:791-800.
56. Ferrara F, Morabito F, Latagliata R, Martino B, Annunziata M, Oliva E, et al. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukaemia relapsing after first complete remission. Haematologica 2000;86:814-20.